P&G Health's FY26 sales up 16%, profit up 30%; innovation and distribution gain
Concall confirmed strong revenue and profit growth. New products beat expectations, distribution added 30k extra-urban pharmacies. No FY27 guidance but management sees sustained momentum.
— 2 earlier stories on Procter & Gamble Health Ltd. →What's new
- FY26 sales of ~₹1,400 cr (+16% YoY); PAT ₹327 cr (+30%).
- Three new product launches beat expectations, contributing early single-digit growth.
- Distribution added ~30,000 pharmacies in extra-urban areas over 2-3 years; Livogen Gummies hit #1 on Amazon.
Why this matters
The numbers confirm P&G Health's ability to drive profitable growth through innovation and distribution expansion, but the results were already disclosed. The concall adds color on execution, not new financials. At a P/E of 32x and ROE of 44%, the stock already prices in strong performance; the call reinforces the narrative.
What we're watching
- Whether innovation-led growth sustains without major new blockbusters.
- Distribution expansion in extra-urban areas and its impact on margins.
- Any future guidance on FY27 if market conditions change.
The full read
P&G Health's FY26 concall confirmed the already-reported numbers. Sales of ₹1,400 crore, up 16%; PAT of ₹327 crore, up 30%. No new financial data. But the call added detail: three new products (Livogen Iron Gummies, Neurobion Nerve Pain Cream, and Evion LC) all beat expectations and together contributed early single-digit growth points. Distribution added 30,000 extra-urban pharmacies over two to three years. E-commerce traction helped Livogen Gummies become Amazon's number-one seller. Management declined to guide for FY27 but cited strong fundamentals and the preventive-health shift. At 32x trailing earnings and a ₹10,487 cr market cap, the stock already reflects sustained execution. The call doesn't change the thesis: it confirms the story is playing out as planned.
Questions answered
- What were the key product innovations driving growth?
- Livogen Iron Gummies, Neurobion Nerve Pain Cream, and Evion LC exceeded expectations and contributed early single-digit growth points to FY26 revenue.
- How much did P&G Health expand its distribution network?
- The company added approximately 30,000 pharmacies in extra-urban areas over two to three years as part of a distribution transformation initiative.
- Why did management decline to provide FY27 guidance?
- Management did not give specific guidance for FY27, but expressed confidence in sustained growth momentum based on brand fundamentals and the preventive health trend.
- What is the e-commerce traction, and which product performed well?
- E-commerce channels gained traction, with Livogen Gummies achieving a number-one ranking on Amazon.
- How do these results compare with the previously reported FY26 numbers?
- The concall confirmed the same FY26 numbers: sales of ₹1,400 cr and PAT of ₹327 cr, which were already disclosed in the audited results. The call provided additional color but no new financial data.
Procter & Gamble Health Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on PGHL →- 18 Jun 2026 · 4:00 PM IST P&G Health's FY26 sales up 16%, profit up 30%; innovation and distribution gain
- 41d ago Procter & Gamble Health posts 30% profit growth for FY26
- 41d ago P&G Health's Q4 profit jumps 55% on strong pharma demand